regimen ['redʒimen]

regimen的基本解释

n.

养生法, 生活规则

• Under such a regimen you'll certainly live long.
• 你这样养生一定可以长寿。

与regimen相关的网络例句 [注：此内容来源于网络，仅供参考]

Meta-analyses showed that the response rate of TP (topotecan + cisplatin) regimen had no significant difference compared with EP regimen (etoposide + cisplatin) with OR 0.83 and 95%CI 0.63 to 1.09, but myelo-suppression such as leucopenia and thrombopenia was more severe with TP regimen; the response rate of monotherapy with topotecan was similar with that of CE (carboplatin + etoposide) regimen with OR 0.59 and 95%CI 0.22 to 1.60; the response rate of TEP (topotecan + etoposide + cisplatin) regimen was comparable with that of EP regimen with OR 1.37 and 95%CI 0.82 to –2.28, but myelosuppression and anemia were more severe with TEP regimen; the response rate with OR 0.97 and 95％CI 0.60 to –1.57, median time to progression with WMD –2.32 and 95％CI –5.72 to 1.09 and median survival time with WMD –1.65 and 95％CI –7.13 to 3.83 of IV topotecan were similar to those of oral topotecan, while neutropenia was more severe with IV topotecan.

Meta分析结果表明，TP 方案与EP方案的反应率相似 [OR 0.83， 95%CI (0.63，1.09)]，但具有相对高的致血小板下降的骨髓毒性；单药拓朴替康与CE方案的反应率相似 [OR 0.59， 95%CI (0.22，1.60)]；TEP方案（拓扑替康＋足叶乙甙＋顺铂）与EP方案的反应率相似 [OR 1.37， 95%CI (0.82，2.28)]，TEP方案致化疗后重度白细胞下降、重度血小板下降、重度血红蛋白下降均高于EP方案；口服拓扑替康与静脉滴注拓扑替康的化疗后反应率 [OR 0.97， 95％CI (0.60，1.57)]、中位疾病进展期 [WMD –2.32， 95％CI (–5.72， 1.09)]、中位生存期 [WMD –1.65， 95％CI (–7.13，3.83)] 相似，口服拓扑替康化疗后重度中性粒细胞下降明显低于静脉滴注拓扑替康。

Meta-analysis based on included studies showed that response rate of TP regimen has no statistic significance compared with EP regimen[OR0.83,95%CI(0.63-1.090)],but myelo-suppression such as leucopenia and thrombopenia is more severe; response rate of single topotecan has no statistic significance compared with CE regimen[OR0.59,95%CI(0.22-1.60)]; response rate of TEP regimen has no statistic significance compared with EP regimen [OR1.37, 95%CI(0.82-2.28)], but myelo-suppression such as leucopenia, thrombopenia and anemia is more severe; response rate of IV topotecan has no statistic significance compared with Oral topotecan[OR0.97, 95%CI(0.60-1.57)],so as median time to progression[WMD-2.32, 95%CI(-5.72,1.09)] and median survival time[WMD-1.65, 95%CI(-7.13,3.83)],while neutropenia is more sever in IV topotecan than Oral topotecan.

分析表明，TP方案与EP方案的反应率相似[OR0.83，95％CI(0.63-1.090)]，但具有相对高的致白细胞和血小板下降的骨髓毒性；单药拓扑替康与CE方案的反应率相似[OR0.59，95％CI(0.22-1.60)]；TEP方案与EP方案的反应率相似[OR1.37，95％CI(0.82-2.28)]，TEP方案致化疗后重度白细胞下降、重度血小板下降、重度血红蛋白下降均高于EP方案；口服拓扑替康与静脉滴注拓扑替康的化疗后反应率[OR0.97，95％CI(0.60-1.57)]、中位疾病进展期[WMD-2.32，95％CI(-5.72，1.09)]、中位生存期[WMD-1.65，95％CI(-7.13，3.83)]相似，口服拓扑替康化疗后重度中性粒细胞下降明显低于静脉滴注拓扑替康。

After a two-week screening period, 18 patients participated in a four-week as-required regimen of 2 mg apomorphine SL, escalated to 3 mg when appropriate after two weeks. Three patients (16.7%) benefited from this treatment modality ( P .05). The nonresponding group of 15 patients continued with a daily regimen of 2 mg apomorphine SL for two weeks followed by 3 mg daily for two weeks. The 3 mg daily regimen was more effective for ED ( P .02) and for each sexual domain scored with the International Index of Erectile Function questionnaire. Adverse events, as reported by three patients (23%) during the 3 mg regimen, were nausea, dizziness, and headache.

在二星期的筛检过程之后，18位病患参与为期四个星期的2mg，在两星期后适当的增加至3mg的阿朴吗啡 SL疗法，其中三位病患(16.7%)受益于这种治疗方法(P 。05)，15位无反应的病患持续接受每日2 mg的阿朴吗啡 SL两周后，再接著以每日3 mg的两周治疗，对于ED及国际勃起功能指数调查表的每项性功能区计分，每日3 mg的疗法比较有效(P 。02)，在接受3 mg疗法期间三位病患( 23%)的不良事件，为恶心、眩晕、和头痛。

与regimen相关的网络解释 [注：此内容来源于网络，仅供参考]

regimen：养生

抗氧化剂和防腐剂(Preservative)稍有不同,3.某人证成的(justified)相信P是真的. 所以他们提出新的养生(regimen)健康食品﹐建议饲主用以餵食宠物、达到养生的延伸诉求.

regimen：养生法

支柱,后盾 prop | 养生法 regimen | 默想;坐禅 meditation

regimen：生活制度

regeneration 再生 | regimen 生活制度 | region 部

regimen：制度

regime 政体 | regimen 制度 | regiment 多数

regimen diet：规定食谱

obesity diet 肥胖病饮食 | prenatal diet 孕期饮食 | regimen diet 规定食谱